Tubulis

Drug Discovery · Planegg-Martinsried, Germany · Founded 2012 · Privately Held (backing)

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. Tubulis is based in Planegg-Martinsried, Germany and was founded in 2012. It was valued at $5.8 billion at a merger or acquisition in Apr 2026, the last priced event on record. It has raised $618 million across 1 recorded round; the latest was a $361 million Series C in Oct 2025.

PMV mark · valuation
$5.8B
Oct 2026
Priced at
a merger or acquisition
Apr 2026
Total raised
$618.5M
Last round
Later Stage VC (Series C)
Oct 2025
How much has Tubulis raised?
$618.5Macross 1 recorded rounds · Oct 2025 – Oct 2025

Most recently, Tubulis raised $360.7M in its Later Stage VC (Series C) (Oct 2025).

Free account
More of Tubulis with a free account
  • ·The complete investor list: 26 names
  • ·Everyone on the team, board and advisors included
  • ·Watch Tubulis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Tubulis round by round

1 rounds
Oct 2025Later Stage VC (Series C)$360.7M▮
+ 1 more investors · free account

How much has Tubulis raised?

Tubulis has raised $618 million in total; 1 of its rounds is on record. The largest on record was a $361 million Series C in Oct 2025.

Tubulis investors

26 investors are on record for Tubulis, including Fidelity Management & Research Company, High-Tech Gründerfonds, Blackstone and Bayern Kapital. By type, the record holds 7 venture capital firms, 2 asset managers and 1 private equity firm. The Series C in Oct 2025 drew 15 investors.

For fundraisers
Raising for a company like Tubulis?

26 investors have backed Tubulis — start your target list with the firms already writing checks in drug discovery.

See all 26 investors →

Frequently asked about Tubulis

How much has Tubulis raised?
Tubulis has raised $618.5M in total across 1 recorded funding rounds.
When was Tubulis's last funding round?
Tubulis's most recent recorded round was Later Stage VC (Series C) in Oct 2025, raising $360.7M.